# US 2021/0171616 A1 · Anti-pacap antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171616 A1
- Document ID: US20210171616A1
- Status: Published application
- Kind: A1
- Application number: 17/175,870
- Filed: 2021-02-15
- Published: 2021-06-10
- Earliest claimed: 2017-09-29
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Chetankumar Natvarlal Patel; Michael Parvin Johnson; Catherine Brautigam Beidler
- Web page: https://patentgrep.com/patent/US20210171616A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/06: Antimigraine agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 38/005: {Enzyme inhibitors (protease inhibitors A61K38/55)}
- A61K 38/1796: {for hormones (for neuromediators A61K38/1787)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Nucleic acids comprising sequences that encode antibodies to human pituitary adenylate cyclase-activating peptide for the manufacture of antibodies to human pituitary adenylate cyclase-activating peptide.

## Claims

### Claim 1

A nucleic acid comprising a sequence encoding SEQ ID NO: 9 or 10.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the sequence encodes SEQ ID NO: 9 and wherein residue 62 is aspartic acid residue 104 is asparagine.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein the sequence encodes SEQ ID NO: 9 and wherein residue 62 is alanine and residue 104 is threonine.

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein the sequence encodes SEQ ID NO: 9 and wherein residue 62 is glutamic acid and residue 104 is threonine.

### Claim 5 (depends on 1)

The nucleic acid of claim 1, wherein the sequence encodes SEQ ID NO: 9 and wherein residue 62 is glutamine and residue 104 is threonine.

### Claim 6 (depends on 1)

The nucleic acid of claim 1, wherein the sequence encodes SEQ ID NO: 10 and wherein residue 30 is serine and residue 55 is leucine.

### Claim 7 (depends on 1)

The nucleic acid of claim 1, wherein the sequence encodes SEQ ID NO: 10 and wherein residue 30 is tryptophan and residue 55 is phenylalanine.

### Claim 8

A nucleic acid comprising a sequence encoding SEQ ID NO: 1 or 2.

### Claim 9 (depends on 8)

The nucleic acid of claim 8, wherein the sequence encodes SEQ ID NO: 1 and wherein residue 62 is aspartic acid, residue 104 is asparagine, residue 231 is proline, residue 237 is alanine and residue 238 is alanine.

### Claim 10 (depends on 8)

The nucleic acid of claim 8, wherein the sequence encodes SEQ ID NO: 1 and wherein residue 62 is alanine, residue 104 is threonine, residue 231 is proline, residue 237 is alanine and residue 238 is alanine.

### Claim 11 (depends on 8)

The nucleic acid of claim 8, wherein the sequence encodes SEQ ID NO: 1 and wherein residue 62 is glutamic acid, residue 104 is threonine, residue 231 is proline, residue 237 is alanine and residue 238 is alanine.

### Claim 12 (depends on 8)

The nucleic acid of claim 8, wherein the sequence encodes SEQ ID NO: 1 and wherein residue 62 is glutamine, residue 104 is threonine, residue 231 is proline, residue 237 is alanine and residue 238 is alanine.

### Claim 13 (depends on 8)

The nucleic acid of claim 8, wherein the sequence encodes SEQ ID NO: 2 and wherein residue 30 is serine and residue 55 is leucine.

### Claim 14 (depends on 8)

The nucleic acid of claim 8, wherein the sequence encodes SEQ ID NO: 2 and wherein residue 30 is tryptophan and residue 55 is phenylalanine.

### Claim 15

A vector comprising:
(a) a first nucleic acid sequence encoding SEQ ID NO: 9 and a second nucleic acid sequence encoding SEQ ID NO: 10; or
(b) a first nucleic acid sequence encoding SEQ ID NO: 1 and a second nucleic acid sequence encoding SEQ ID NO: 2.

### Claim 16 (depends on 15)

The vector of claim 15, wherein the first nucleic acid sequence encodes SEQ ID NO: 9 and the second nucleic acid sequence encodes SEQ ID NO: 10 and wherein, residue 62 of SEQ ID NO: 9 is aspartic acid, residue 104 of SEQ ID NO: 9 is asparagine, residue 30 of SEQ ID NO: 10 is serine and residue 55 of SEQ ID NO: 10 is leucine.

### Claim 17 (depends on 15)

The vector of claim 15, wherein the first nucleic acid sequence encodes SEQ ID NO: 9 and the second nucleic acid sequence encodes SEQ ID NO: 10 and wherein, residue 62 of SEQ ID NO: 9 is alanine, residue 104 of SEQ ID NO: 9 is threonine, residue 30 of SEQ ID NO: 10 is tryptophan and residue 55 of SEQ ID NO: 10 is phenylalanine.

### Claim 18 (depends on 15)

The vector of claim 15, wherein the first nucleic acid sequence encodes SEQ ID NO: 9 and the second nucleic acid sequence encodes SEQ ID NO: 10 and wherein, residue 62 of SEQ ID NO: 9 is glutamic acid, residue 104 of SEQ ID NO: 9 is threonine, residue 30 of SEQ ID NO: 10 is tryptophan and residue 55 of SEQ ID NO: 10 is phenylalanine.

### Claim 19 (depends on 15)

The vector of claim 15, wherein the first nucleic acid sequence encodes SEQ ID NO: 9 and the second nucleic acid sequence encodes SEQ ID NO: 10 and wherein, residue 62 of SEQ ID NO: 9 is glutamine, residue 104 of SEQ ID NO: 9 is threonine, residue 30 of SEQ ID NO: 10 is tryptophan and residue 55 of SEQ ID NO: 10 is phenylalanine.

### Claim 20 (depends on 15)

The vector of claim 15, wherein the first nucleic acid sequence encodes SEQ ID NO: 1 and the second nucleic acid sequence encodes SEQ ID NO: 2 and wherein, residue 62 of SEQ ID NO: 1 is aspartic acid, residue 104 of SEQ ID NO: 1 is asparagine, residue 231 of SEQ ID NO: 1 is proline, residue 237 of SEQ ID NO: 1 is alanine, residue 238 of SEQ ID NO: 1 is alanine, residue 30 of SEQ ID NO: 2 is serine and residue 55 of SEQ ID NO: 2 is leucine.

### Claim 21 (depends on 15)

The vector of claim 15, wherein the first nucleic acid sequence encodes SEQ ID NO: 1 and the second nucleic acid sequence encodes SEQ ID NO: 2 and wherein, residue 62 of SEQ ID NO: 1 is alanine, residue 104 of SEQ ID NO: 1 is threonine, residue 231 of SEQ ID NO: 1 is proline, residue 237 of SEQ ID NO: 1 is alanine, residue 238 of SEQ ID NO: 1 is alanine, residue 30 of SEQ ID NO: 2 is tryptophan and residue 55 of SEQ ID NO: 2 is phenylalanine.

### Claim 22 (depends on 15)

The vector of claim 15, wherein the first nucleic acid sequence encodes SEQ ID NO: 1 and the second nucleic acid sequence encodes SEQ ID NO: 2 and wherein, residue 62 of SEQ ID NO: 1 is glutamic acid, residue 104 of SEQ ID NO: 1 is threonine, residue 231 of SEQ ID NO: 1 is proline, residue 237 of SEQ ID NO: 1 is alanine, residue 238 of SEQ ID NO: 1 is alanine, residue 30 of SEQ ID NO: 2 is tryptophan and residue 55 of SEQ ID NO: 2 is phenylalanine.

### Claim 23 (depends on 15)

The vector of claim 15, wherein the first nucleic acid sequence encodes SEQ ID NO: 1 and the second nucleic acid sequence encodes SEQ ID NO: 2 and wherein, residue 62 of SEQ ID NO: 1 is glutamine, residue 104 of SEQ ID NO: 1 is threonine, residue 231 of SEQ ID NO: 1 is proline, residue 237 of SEQ ID NO: 1 is alanine, residue 238 of SEQ ID NO: 1 is alanine, residue 30 of SEQ ID NO: 2 is tryptophan and residue 55 of SEQ ID NO: 2 is phenylalanine.
